Open Access

Ovarian Sertoli–Leydig cell tumors: MRI findings and pathological correlation

Journal of Ovarian Research20136:73

DOI: 10.1186/1757-2215-6-73

Received: 15 July 2013

Accepted: 21 October 2013

Published: 26 October 2013

Abstract

Background

To investigate the magnetic resonance imaging (MRI) characteristics of ovarian Sertoli-Leydig cell tumors (SLCT).

Methods

The clinical, MRI and pathological findings of five cases of SLCT were reviewed retrospectively. MRI appearances of tumors including laterality, shape and size, architecture, wall, septa and vegetation, signal intensity and contrast-enhancement pattern were evaluated and correlated with pathological findings.

Results

Two tumors were solid which appeared as low signal intensity on T1-weighted imaging (T1WI) and moderate on T2-weighted imaging (T2WI) with multiple small cysts in one of them. The remaining three SLCT were multilocular cystic with the irregularly thickened wall and septa, and with solid area and mural nodules in one of them. The cystic components had the same signal intensity as urine. All the solid components were intensely enhanced after administration of contrast medium. All five tumors were pathologically intermediate differentiation and at FIGO stage I.

Conclusions

SLCT demonstrate variable MRI morphological appearances. However, the irregularly thickened wall and septa, the moderate T2WI signal intensity and obvious enhancement in the solid components are three MRI features.

Keywords

Ovary Sertoli-Leydig cell tumors Magnetic resonance imaging Pathology

Background

Sertoli-Leydig cell tumors (SLCT) of ovary are a rare type but well defined clinicopathologic entity of sex cord-stromal tumors, accounting for less than 0.5% of ovarian neoplasms [1]. These tumors are histopathologically characterized by the presence of variable proportions of Sertoli and Leydig cells. Most SLCT occur in young women and are at stage I (International Federation of Gynecology and Obstetrics, FIGO) [2]. Conservative surgery is acceptable for young patients who wish to preserve fertility without compromising 5-year disease-specific survival [3]. Some clinicopathological studies of SLCT have been reported. To our knowledge, however, only three imaging case reports have been published [46]. The present study described the magnetic resonance imaging (MRI) appearances of five patients with SLCT by correlated with pathological findings, with the aim to be familiar with the imaging appearances of this entity and improve the accuracy of preoperative diagnosis.

Methods

Patients

This retrospective study was approved by the institutional review boards of our hospitals and informed consent was waived. Patients with suspected ovarian tumor were enrolled in an ovarian tumor MRI study project from February 2008 to November 2012 at Jinshan Hospital and Obstetrics & Gynecology Hospital of Fudan University. Among 530 cases proven by surgery and histopathology, a total of five patients with SLCT were found.

MRI scan and analysis

All patients were performed with 1.5-T MRI scanners (Avanto or Symphony, Siemens, Erlangen, Germany) using a torso phased-array coil with patient supine and free breathing. The following sequences were obtained: spin echo (SE) axial T1-weighted imaging (T1WI ) [time of repetition (TR)/time of echo (TE), 340 ms/10 ms]; fast low-angle shot (FLASH) 2D T1WI with fat saturation (TR/TE, 196 ms/2.9 ms); turbo spin echo (TSE) T2-weighted imaging (T2WI) with and without fat saturation (TR/TE, 8000 ms/83 ms and 4000 ms/98 ms) respectively. Sagittal and coronal TSE T2WI (TR/TE, 8000 ms/98 ms) were also obtained. The contrast-enhanced FLASH 2D T1WI with fat saturation (TR/TE, 196 ms/2.9 ms) was performed in the axial, sagittal and coronal planes right after intravenous administration of Gadopentetate dimeglumine (Gd-DTPA, Magnevist; Bayer Schering, Guangzhou, China) at a dose of 0.1 mmol/kg of body weight and a rate of 2 ml/s. The scanning parameters were as follows: 5-mm slice thickness, 1.5-mm gap, 256 × 256 matrix, 20–25 cm × 34 cm field of view and four excitations. The scanning range was from the inferior pubic symphysis to the renal hilum and was extended beyond the dome of tumor in the cases with huge masses.

The MR images were reviewed independently by two radiologists who specialized in gynecological imaging. Their interpretations were arrived at by consensus. The following features were evaluated: (a) laterality, shape and size; (b) cystic or solid components; (c) thickness of wall and septa (considered thin when ≤3 mm and thick when > 3mm); (d) vegetations; (e) signal intensity (the signal similar to inner, outer myometrium and fat was considered low, moderate and high, respectively); (f) contrast-enhancement (the enhancement of solid component less than or equal to that of innermyometrium, between inner and outer myometrium, and equal to or greater than outer myometrium was considered mild, moderate or obvious, respectively). The predominant signal was taken to represent the tumor’s signal, where the tumor was heterogeneous.

Pathological analysis

Histopathological examination was performed by a radiologist and a pathologist, both were familiar with or specialized in gynecological pathology. After determining the shape and size of the tumors, the gross specimens were dissected into 1 to 5 cm sections. The tumors were analyzed including: shape, size, architecture, the presence of loculus and the nature of the intracystic content; thickness of wall and septa. The specimens were fixed in 10% formalin solution, embedded in paraffin, sectioned, stained with hematoxylin and eosin (H&E), immunohistochemical inhinbin-α, EMA and cytokeratin 7. A correlation between imaging and histopathological findings was performed together by a pathologist and a radiologist.

Results and discussion

Only one of five patients presented with deepening of the voice and increasing of facial hair. Three cases presented with abdominal swelling. The remaining case was asymptomatic and found during the routine physical examination. Serum testosterone level (normal, 0.15-0.5 ng/ml) elevated in two cases, and CA125 level (normal, < 35 U/ml) elevated in one. Radical surgery was performed in two cases, unilateral salpingo-oophorectomy in one case, and cystectomy in the other two. The clinical manifestations of five cases of SLCT are listed in Table 1.
Table 1

The clinical manifestations of five cases of Sertoli-Leydig cell tumors

Case no.

Age

Symptoms

CA125

Testo

Surgery

Pathological differentiation

FIGO stage

1

30

Virilization

11.8

5.9

LAUC

Intermediately

Ia

2

46

None

\

\

TRS#

Intermediately

Ia

3

22

Abdominal swelling

92.9

\

LAUC

Intermediately

Ia

4

56

Abdominal swelling

24

1.51

TRS

Intermediately *

Ia

5

25

Abdominal swelling

\

\

LAUS

Intermediately

Ia

CA125 (normal, <35 U/ml); Testo = Testosterone (normal, 0.15-0.5 ng/ml); LAUC = Laproscopically assisted unilateral cystectomy; LAUS = Laproscopically assisted unilateral salpingo-oophorectomy. TRS = Transabdominal radical surgery (total hysterectomy and bilateral salpingo-oophorectomy); # TRS followed by chemotherapy. * Intermediately differentated with mucinous heterologous.

MRI findings of five cases of SLCT are summarized in Table 2. Four tumors occurred in left ovary and the remaining one in right ovary; two tumors were solid with the round shape and demarcatedmargin (Figure 1). Multiple small cysts were found in one of the solid tumors. The signal intensities of solid masses were low on T1WI and moderate on T2WI. Three tumors were multilocular cystic (2, 10 and 12 loculi respectively) with irregularly thickened wall and septa, and one of them had solid area and mural nodules with a broad base. The signal intensities of the solid area (Figure 2A) and nodules were the same as those of the solid tumors. The signal intensities of the cystic components were the same as those of the urine. After administration of contrast medium, the cystic wall and septa (Figure 3B), solid area and nodules, and solid masses were enhanced intensely which was iso- to hyperintense to that of outer myometrium. Small amount of ascites were found in three cases. However, no extension to the pelvic organs, peritoneal inplants and enlarged lymph nodes was observed.
Table 2

The MRI findings of five cases of Sertoli-Leydig cell tumors

Case no

Site

Size (cm 3)

Components

SI (solid)

SI (cystic)

Enhancement (solid)

T1WI

T2WI

T1WI

T2WI

1

Left

6.6×6.1×6.2

Purely solid

Low

Moderate

\

\

Intense

2

Right

4.7×5.0×4.2

Mainly solid#

Low

Moderate

Low

High

Intense

3

Left

25×20×38

Mainly cystic*

Low

Moderate

Low

High

Intense

4

Left

20×15×15

Purely cystic

Low

Moderate

Low

High

Intense

5

Left

3.7×4.3×4.3

Purely cystic

Low

Moderate

Moderate/low

High

Intense

SI = Signal Intensity; # Mainly Solid with multiple small cysts; * Mainly Cystic with intracystic solid area and mural nodules.

Figure 1

Sertoli-Leydig cell tumor in a 46-year-old woman without symptoms. (A) Axial T2-weighted image with fat saturation shows a solid mass with multiple small cysts (arrow). (B) The solid components are the moderate signal intensity and obviously enhanced after the administration of contrast medium.

Figure 2

Sertoli-Leydig cell tumor in a 22-year-old woman with irregular menses and abdominal swelling. Sagittal T2-weighted image demonstrates a huge multilocular cystic mass with solid area and mural nodules (white arrow), which are the moderate signal intensity (A) and enhanced intensely after the administration of contrast medium (B). (C) Grossly, the tumor shows an encapsulated cystic mass (fluid has been removed) with reddish solid area and yellowish nodules (black arrow). (D) Microscopically, Leydig cells (arrowhead) are sparse in the background of Sertoli cells, which arrange in closed tubules (black arrow). The sertoli cells have abundant vacuolated cytoplasm filled with lipid (H&E×400). (E) The sex cord areas stain strongly for α-inhibin (α-inhibin stain ×200).

Figure 3

Sertoli-Leydig cell tumor in a 25-year-old woman with irregular menses. Axial T2-weighted image with fat saturation (A) shows a bilocular cystic mass with thickened septa and wall (arrow), which are intensely enhanced (B).

The macroscopic appearances confirmed the MRI morphological findings (Figure 2C). Histopathologically, Leydig cells had the eosinophilic cytoplasm, scattering in the background of numerous Sertoli cells, some of which have abundant vacuolated cytoplasm filled with lipid (Figure 2D). A few cords and poorly developed tubules of Sertoli cells were found, with some atypia. The immunohistochemical analysis showed that sex cord-stromal cells stained intensely positive for inhinbin-α and negative for the cytokeratin 7 receptors. The mucinous components expressed strong cytoplasmic positivity for cytokeratin 7.

SLCT are the most common virilizing ovarian tumors and originally named as arrhenoblastomas or androblastomas. However, some tumors are nonfunctioning, and even estrogenic. Therefore, World Health Organization renamed them as “Sertoli-Leydig cell tumors” according to their histopathological features [7]. Young et al. [2] reviewed the clinicopathological data of 207 patients with SLCT. Their ages ranged from 2 to 75 years (average 25 years), with about 75% of the patients being 30 years or younger and less than 10% over 50 years; about one-third of the patients presented an elevation of androgen or related symptoms and signs and most of the patients without hormonal effects complained abdominal swelling or pain. Similar findings had also been reported [811]. The largest tumor in Young et al.’ series was 51 cm in diameter (average 13.5 cm) and 97.5% of patients were at FIGO stageI, 1.5% at stage II, and 1% at stage III. Tumors usually occured unilaterally, only 1.5% involved both ovaries. Thirty-eight percent of the tumors were solid, 58% solid and cystic, and 4% cystic. Most of SLCT behave in a benign fashion with biologic behavior correlating with degree of differentiation and stage [2, 12]. In our series, mean age was 38.5 years. The tumors were intermediately-differentiated and at stage I in all five cases.

Pathologically, SLCT are divided into four subtypes: well- (11%), intermediately- (54%), and poorly-differentiated (13%) and contained heterologous elements (22%). Heterologous elements are various, such as carcinoid, mesenchymal, and mucinous epithelial tissues with the commonest being gastrointestinal-types [13, 14]. Retiform pattern presents in 15% of SLCT, and is found only in intermediately and poorly differentiated SLCT, and often occurs in younger women [2, 15, 16]. SLCT contain Sertoli cells, Leydig cells, gonadal stromal cells and heterologous cells in tumors with heterologous elements. Leydig cells scatter among numerous Sertoli cells, which may arrange into open or closed tubules. The Sertoli cells may have intracytoplasmic lipids, which may explain the yellowish nodules inside encapsulated mass [6, 8, 17]. And the intracelluar lipid can not be detected by fat saturation. Immunohistochemical staining is positive for alpha-inhibin (sex cord-stromal marker) and positive for cytokeratin 7 for the mucinous elements [1].

In our study, there were two solid and three cystic masses. SLCT showed some MRI features: the irregularly thickened wall and septa, the moderate signal intensity in the solid components on T2WI, which is accordance with previous literatures [6, 17], and the obvious enhancement of the solid components after administration of Gd-DTPA. Azuma et al. [5] reported one case of multilocular cystic SLCT, which demonstrated hyperintensity on T1WI and hypointensity on T2WI considering the hemorrhagic nature of the fluid. In our series, however, the signal intensities of the cystic components were the same as those of the urine.

All five SLCT were misdiagnosed in preoperative MRI in our series. Two solid SLCT were misdiagnosed as fibrothecoma. The mild to moderate enhancement in the latter would be helpful in differentiating from SLCT. In addition, solid SLCT should be distinguished from granulosa cell tumors and ovarian carcinomas which often have appearances of estrogen-producing or irregular necrosis. Three cystic tumors were misdiagnosed as cystadenoma. The cystic SLCT shares the similar gross appearances with ovarian cystadenoma due in part to the mucinous heterologous elements [18]. However, the signal intensity in different loculi of cystadenoma is frequently heterogeneous [19]. The presence of intracystic nodules calls for the need of the differentiation of cystic SLCT from borderline/malignant serous or mucinous tumors. In our case, the nodules are of broad base which is different from the narrow base of papillary projections in epithelial tumors [17].

Conclusions

SLCT are rare and demonstrate variable MRI morphological appearances, they should be considered in young female with virilization, especially in solid or multilocular cystic masses, with an irregularly thickened wall and septa, a moderate signal intensity on T2WI and an obvious enhancement in solid components.

Declarations

Acknowledgement

Grants from Shanghai Municipal Science & Technology Commission (No. 124119a3300) and Shanghai Municipal Health Bureau, China (No. 2008–196).

Authors’ Affiliations

(1)
Department of Radiology, Jinshan Hospital, Shanghai Medical College, Fudan University
(2)
Department of Radiology, Obsterics & Gynecology Hospital, Shanghai Medical College, Fudan University
(3)
Department of Pathology, Jinshan Hospital, Shanghai Medical College, Fudan University

References

  1. Tavassoli FA, Mooney E, Gersell DJ, McCluggage WG, Konishi I, Fujii S, Kiyokawa T, Schwartz P, Kubik-Huch RA, Roth LM: Sex cord-stromal tumors. pathology and genetics of tumors of the breast and female genital organs. Lyon: International Agency for Research on Cancer (IARC); 2003:153–156.Google Scholar
  2. Young RH, Scully RE: Ovarian Sertoli-Leydig cell tumors - a clinicopathological analysis of 207 cases. Am J Sur Pathol 1985, 9: 543–569. 10.1097/00000478-198508000-00001View ArticleGoogle Scholar
  3. Gui T, Cao D, Shen K, Yang J, Zhang Y, Yu Q, Wan X, Xiang Y, Xiao Y, Guo L: A clinicopathological analysis of 40 cases of ovarian Sertoli-Leydig cell tumors. Gynecol Oncol 2012, 127: 384–389. 10.1016/j.ygyno.2012.07.114PubMedView ArticleGoogle Scholar
  4. Niedziela M: Virilizing ovarian tumor in a 14-year-old female with a prior familial multinodular goiter. Pediatr Blood Cancer 2008, 51: 543–545. 10.1002/pbc.21675PubMedView ArticleGoogle Scholar
  5. Azuma A, Koyama T, Mikami Y, Tamai K, Fujimoto K, Morisawa N, Nagano F, Yoshioka S, Togashi K: A case of Sertoli-Leydig cell tumour of the ovary with a multilocular cystic appearance on CT and MR imaging. Pediatr Radiol 2008, 38: 898–901. 10.1007/s00247-008-0868-zPubMedView ArticleGoogle Scholar
  6. Outwater EK, Marchetto B, Wagner BJ: Virilizing tumors of the ovary: imaging features. Ultrasound Obstet Gynecol 2000, 15: 365–371. 10.1046/j.1469-0705.2000.00123.xPubMedView ArticleGoogle Scholar
  7. Dolge OG: Typing of Ovarian Tumors (International Histological Classification of Tumours, No.9). Geneva: World Health Organization; 1973.Google Scholar
  8. Tanaka YO, Tsunoda H, Kitagawa Y, Ueno T, Yoshikawa H, Saida Y: Functioning ovarian tumors: direct and indirect findings at MR imaging. Radiographics 2004,24(Suppl 1):147–166.View ArticleGoogle Scholar
  9. Shi JL, Guo LN, Lang JH: Advances in Sertoli-Leydig cell tumour of the ovary. Zhonghua Bing Li Xue Za Zhi 2008, 37: 631–633.PubMedGoogle Scholar
  10. Choong CS, Fuller PJ, Chu S, Jeske Y, Bowling F, Brown R, Borzi P, Balazs ND, Suppiah R, Cotterill AM, Payton D, Robertson DM, Burger HG: Sertoli-Leydig cell tumor of the ovary, a rare cause of precocious puberty in a 12-month-old infant. J Clin Endocrinol Metab 2002, 87: 49–56. 10.1210/jc.87.1.49PubMedView ArticleGoogle Scholar
  11. Caringella A, Loizzi V, Resta L, Ferreri R, Loverro G: A case of Sertoli-Leydig cell tumor in a postmenopausal woman. Int J Gynecol Cancer 2006, 16: 435–438. 10.1111/j.1525-1438.2006.00203.xPubMedView ArticleGoogle Scholar
  12. Zhang M, Cheung MK, Shin JY, Kapp DS, Husain A, Teng NN, Berek JS, Osann K, Chan JK: Prognostic factors responsible for survival in sex cord stromal tumors of the ovary-an analysis of 376 women. Gynecol Oncol 2007, 104: 396–400. 10.1016/j.ygyno.2006.08.032PubMedView ArticleGoogle Scholar
  13. Zaloudek C, Norris HJ: Sertoli-Leydig tumors of the ovary. A clinicopathologic study of 64 intermediate and poorly differentiated neoplasms. Am J Surg Pathol 1984, 8: 405–418. 10.1097/00000478-198406000-00001PubMedView ArticleGoogle Scholar
  14. Young RH, Prat J, Scully RE: Ovarian Sertoli-Leydig cell tumors with heterologous elements. I. Gastrointestinal epithelium and carcinoid: a clinicopathologic analysis of thirty-six cases. Cancer 1982, 50: 2448–2456. 10.1002/1097-0142(19821201)50:11<2448::AID-CNCR2820501133>3.0.CO;2-TPubMedView ArticleGoogle Scholar
  15. Mooney EE, Nogales FF, Bergeron C, Tavassoli FA: Retiform Sertoli-Leydig cell tumours: clinical, morphological and immunohistochemical findings. Histology 2002, 41: 110–117.Google Scholar
  16. Young RH: Sertoli-Leydig cell tumors of the ovary - review with emphasis on histologic aspects and unusual variants. Gynecol Oncol 1993, 12: 141–147.Google Scholar
  17. Jung SE, Lee JM, Rha SE, Byun JY, Jung JI, Hahn ST: CT and MR Imaging of ovarian tumors with emphasis on differential diagnosis. Radiographics 2002, 22: 1305–1325. 10.1148/rg.226025033PubMedView ArticleGoogle Scholar
  18. Jung SE, Rha SE, Lee JM, Park SY, Oh SN, Cho KS, Lee EJ, Byun JY, Hahn ST: CT and MRI findings of sex cord-stromal tumor of the ovary. AJR Am J Roentgenol 2005, 185: 207–215. 10.2214/ajr.185.1.01850207PubMedView ArticleGoogle Scholar
  19. Ghossain MA, Buy JN, Ligneres C, Bazot M, Hassen K, Malbec L, Hugol D, Truc JB, Decroix Y, Poitout P: Epithelial tumors of the ovary: comparison of MR and CT findings. Radiology 1991, 181: 863–870.PubMedView ArticleGoogle Scholar

Copyright

© Cai et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement